Ann: Change in substantial holding, page-72

You nailed it there @Aqua65 , the science and the results we have seen released on Ovarian and Breast cancer recently, speak loud and clear, everything else is background waffle.

Focus on the results and the market cap of Race Oncology and this is still a screaming buy and hold.

The below results are outstanding , could be an absolute game changer in the treatment for cancer sufferers, and best of all it's only part of the Race Oncology unfolding story.



https://hotcopper.com.au/threads/ann-positive-early-preclinical-ovarian-cancer-results.5921579/

Positive Early Preclinical Ovarian Cancer Results

 Bisantrene found to be more effective compared to doxorubicin and epirubicin
in ovarian cancer cell lines

 Bisantrene killed ovarian cancer cells resistant to the current standard of care
chemotherapeutic agents cisplatin, 5-fluorouracil and chlorambucil

 These preclinical results are encouraging and consistent with past Phase II
clinical trials which identified Bisantrene as an effective ovarian cancer
treatment.

Conclusions

• Bisantrene was found to kill ovarian cancer cells confirming the historical Phase II
clinical trials

• Bisantrene was able to kill ovarian cancer cells resistant to cisplatin, 5-fluorouracil
and chlorambucil

• These data support further assessment of Bisantrene as an alternative
chemotherapeutic agent in ovarian cancer patients.


https://hotcopper.com.au/threads/ann-compelling-preclinical-breast-cancer-results.5949214/

Compelling Preclinical Breast Cancer Results

§ Bisantrene killed breast cancer cells resistant to the current standard of care
breast cancer drugs etoposide, palbocicclib, fulvestrant, tamoxifen, doxorubicin,
epirubicin and cyclophosphamide

§ Bisantrene was found to kill breast cancer cells from all common breast cancer
subtypes including triple negative, ER+, and Her2+

§ These results clearly support advancing Bisantrene into human breast cancer
clinical trials

Conclusions

• Bisantrene was found to kill breast cancer cells across a wide range of different
subtypes, including triple negative, HER2 positive, and estrogen receptor
positive.

• Bisantrene showed additive cell death effects when combined with
cyclophosphamide that are very similar to that seen when cyclophosphamide is
used in combination with doxorubicin or epirubicin

• Bisantrene was able to kill breast cancers cells resistant to etoposide,
palbocicclib, fulvestrant, tamoxifen, doxorubicin, epirubicin & cyclophosphamide

• Bisantrene was less toxic to non-tumorous breast cancer cells than either
doxorubicin or epirubicin, suggesting a more precisely targeted mechanism of
action

• These data support the use of Bisantrene not only as a heart friendlier
alternative to doxorubicin or epirubicin, but also as a possible salvage treatment
in heavily pretreated metastatic breast cancer patients.